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between HIV/AIDS patients (37/52) and BD (113/150).
Concurrent latent/persistent HHV-6 and HHV-7 infections
was found much more often in CFS patients (25/49) and
patients with HIV infection (32/52) in comparison with
BD (49/150). The freguency of active HHV-7 infections
signiﬁcally higher in HIV/AIDS patients (19/37) in comparison
with BD (12/113). Active concurrent herpesvirus infections
were observed in HIV/AIDS (10/32) and (9/25) CFS patients
only.
Conclusion: Active infection with both HHV-6 and HHV-7
more frequent in patients with CFS and HIV/AIDS than in
BD.
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Sciences, Bir Hospital, Kathmandu, Nepal
Backgrounda and Aim: Before the availability of pegylated
interferon, interferon therapy in chronic hepatitis C patients
was almost a failure in Nepal. This study was carried out to
determine the efﬁcacy of peg-interferon (2a) plus ribavirin
in Nepali patients.
Method: Thirty-seven consecutive patients with anti HCV
test report were enrolled in the study from April 2004
to December 2007. Chronic hepatitis was conﬁrmed by
raised aminotransferase and presence of HCV RNA by PCR.
Peg-interferon was given in a dose of 180 mcg per week
subcutaneously and dose was adjusted whenever required.
Ribavirin was given in a dose of 800 1000mg/day. Viral load
was repeated after 4th dose, 12th dose, last dose, after 3
month and 6 month of treatment.
Results: Thirty-ﬁve patients showed detectable HCV RNA
by PCR. 30 patients were treated and 29 followed up as 1
patient was lost in follow up. The genotype was 1 in 5, 2
in 9, 3 in 15 patients. 14 patients were super responder (9
type 3 and 5 type 2), while 12 patients were free of virus
after 12 weeks of treatment. End treatment response (ETR)
was 100% and sustained viral response (SVR) was achieved
in 96.5%. Neutropenia was the commonest side effect of
interferon while side effects of ribavirin were not seen.
Conclusions: Peg-interferon and ribavirin was well tolerated
in Nepali patient. ETR was 100% and SVR was 96.5% in small
cohort of patient. 12 weeks therapy may be considered in
type 2 and 3 due to cost factor.
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Objective: To conduct conﬁrmative study of anti-
HCV positive samples deemed positive by the second-
tier and third-tier hospitals in China using two fully
automatic chemiluminescent assay instrument, i2000
(ARCHITECT iSystem) and ECI (the Ortho-Clinical
Diagnostics Vitros ECI Anti-HCV with the use of the
CHIRON RIBA (Recombinant Immunoblot Assay) HCV3.0strip
immunoblot assay (SIA) method. For the purpose to evaluate
the rationality positive boundary value of the s/co for
screening the HCV-positive samples. A boundary value of
s/co has been speciﬁed such that any sample screened
positive with s/co ratio greater than the boundary value
would be at least better than 95% truly positive and
therefore need not to undergo conﬁrmatory RIBA test. more
accurate clinical diagnosis of HCV case.
Methods: First, screen out Anti-HCV samples that signal-to-
cutoff (s/co) is 1 20 in the ARCHITECT-i2000 or the Vitros ECI
is 1 35. Then, Chiron RIBA HCV3.0 SIA test was performed
to conﬁrm the Anti-HCV serological results from the two
companies’ instruments. Followed by checking the HCV RNA
with real time PCR. Lastly, perform statistical ROC curve
processing to determine the boundary value of S/CO for
screening anti-HCVpositive samples.
Results: Among the 203 samples, 33 (16%) were conﬁrmed
RIBA negative and HCV RNA negative; 93samples (46%) were
found RIBA positive but in which only 30 (32.3%) samples
were also HCV RNA positive, 77 samples (38%) were found
RIBA indeterminate and HCV RNA negative. In terms of
sensitivity, the ARCHITECT i2000 analyzer is 99% and the
Vitros ECI was found to be 100%. In terms of speciﬁcity, the
ARCHITECT i2000 was found to be 61%; The Vitros ECI to
be 52%. In terms of anti-HCV position predictive value, the
ARCHITECT i2000 analyzer was 100% on s/co > 6.06 while the
Vitros ECI analyzer was 100% on s/co > 12.35.
Conclusion: The criteria of Anti-HCV s/co > 1 is reasonable
for screening test using fully automatic Chemiluminescent
assay with assurance of sensitivity greater than 97%.
The anti-HCV positive samples can be fairly conﬁrmed if
s/co > 6.05 is measured by the architect I2000 analyzer and
s/co > 12.35 is measured by the Vitros ECI analyzer. When
s/co is measured 1.0 6.5 by the ARCHITECT i2000 analyzer
and 1.0 12.5 by the Vitros ECI analyzer, it is suggested to
perform conﬁrmatory RIBA HCV3.0 SIA test if affordable or
perform HCV RNA test, but it may be more realistic to have
periodic re-examination of anti-HCV samples.
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Background and Aims: Helicobacter pylori is a recognized
type I carcinogen. Although there is a mouse model,
where liver ﬁbrosis and hepatocellular carcinoma (HCC)
are induced by infection with H. hepaticus, pathogenicity of
enterohepatic Helicobacter (EHS) in man is still undeﬁned.
Methods: 105 liver biopsies, 60 from patients with chronic
hepatitis C infection and 45 from patients with HCV
infection and HCC were collected in Egypt. Helicobacter
DNA was detected by genus-speciﬁc 16S rDNA PCR and DNA
sequencing (BLAST). Sera were tested for antibodies of
different Helicobacter species (EIA, Immunoblot).
Results: 16S rDNA were found positive in 52.4%. In chronic
HCV without HCC 51.7% while in chronic HCV with HCC
53.3% were positive respectively. H. hepaticus DNA was
detected in chronic HCV without HCC in 35% and in 13.3%
in chronic HCV with HCC. Antibody detection was positive
in patients with hepatitis C without HCC for H. pylori in
67% and H. hepaticus in 22% while antibody detection was
positive for H. pylori in 64% and H. hepaticus in 16% in
patients with HCC.
